Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-analysis

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3110-3116

  Giacchetti, S ^a,b,c   Dugue P A ^a,b,c   Innominato, P F ^a,b,c   Bjarnason, G A ^d   Focan, C ^e   Garufi, C ^f   Tumolo, S ^g   Coudert, B ^h   Iacobelli, S ⁱ   Smaaland, R ^j,k   Tampellini, M ^l   Adam, R ^a,b,c,m   Moreau, T ^c   Levi F ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d UNIVERSITY OF TORONTO   (Canada)

^e Clinique Saint Joseph   (Belgium)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^h Biostatistic and Quality of Life Unit Georges François Leclerc Center   (France)

ⁱ UNIVERSITY OF CHIETI   (Italy)

^j STAVANGER UNIVERSITY HOSPITAL   (Norway)

^k UNIVERSITY OF BERGEN   (Norway)

^l UNIVERSITY OF TURIN   (Italy)

^m Hepato biliary Center   (France)

more..

Author keywords

Chronotherapy; Colorectal cancer; Drug delivery; Folfox; Gender; Meta analysis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84869825534     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds148     Document Type: Article

References (32)

1. Levi F, Okyar A, Dulong S et al. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 2010; 50: 377-421.
2. Zhang EE, Kay SA. Clocks not winding down: unravelling circadian networks. Nat Rev Mol Cell Biol 2010; 11: 764-776.
3. Innominato PF, Focan C, Gorlia T et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 2009; 69: 4700-4707.
4. Innominato PF, Palesh O, Dhabhar FS et al. Regulation of circadian rhythms and hypothalamic-pituitary-adrenal axis: an overlooked interaction in cancer. Lancet Oncol 2010; 11: 816-817.
5. Li XM, Delaunay F, Dulong S et al. Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res 2010; 70: 3351-3360.
6. Lévi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 2007; 47: 593-628.
7. Lévi F, Zidani R, Vannetzel JM et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multiinstitutional trial. J Natl Cancer Inst 1994; 86: 1608-1617.
8. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350: 681-686.
9. Giacchetti S, Bjarnason G, Garufi C et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24: 3562-3569.
10. Petit E, Milano G, Levi F et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676-1679.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269, W264.
12. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.
13. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
14. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
15. Cassidy J, Clarke S, Diaz-Rubio E et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105: 58-64.
16. Levi F, Karaboue A, Gorden L et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol 2011; 67: 339-348.
17. Rich T, Innominato PF, Boerner J et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11: 1757-1764.
18. Adam R, Wicherts DA, de Haas RJ et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27: 1829-1835.
19. Smith RE, Colangelo L, Wieand HS et al. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 2004; 96: 1128-1132.
20. Adler NE. When separate is more equal. J Am Med Assoc 2010; 304: 2738-2739.
21. Elsaleh H, Joseph D, Grieu F et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-1750.
22. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
23. Press OA, Zhang W, Gordon MA et al. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res 2008; 68: 3037-3042.
24. Karatsoreos IN, Butler MP, Lesauter J, Silver R. Androgens modulate structure and function of the suprachiasmatic nucleus brain clock. Endocrinology 2011; 152: 1970-1978.
25. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
26. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005; 103: 1165-1171.
27. Milano G, Etienne MC, Cassuto-Viguier E et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10: 1171-1175.
28. Shitara K, Matsuo K, Takahari D et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer 2009; 45: 1757-1763.
29. Innominato PF, Giacchetti S, Moreau T et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int 2011; 28: 586-600.
30. Levi F, Focan C, Karaboue A et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 2007; 59: 1015-1035.
31. Cain SW, Dennison CF, Zeitzer JM et al. Sex differences in phase angle of entrainment and melatonin amplitude in humans. J Biol Rhythms 2010; 25: 288-296.
32. Bjarnason GA. Gender differences in rhythmic gene expression in human chronic lymphocytic leukemia cells and T-cells in nine patients: Impact of melatonin therapy on the timing of peak expression. In 12th Biennial Meeting of the Society for Research on Biological Rhythms. Sandestin, FL, USA: 2010; abstr S29.